Abstract: Pancreatic cancer (PC) is a type of digestive tract cancer that is associated with high rates of malignancy and mortality. Resectable PC (RPC) is a type of PC that can be surgically resected. In recent years, clinical research has revealed that the overall survival (OS) of patients with RPC treated with adjuvant chemotherapy is prolonged. However, the overall prognosis is still not optimistic. Currently, there is no standard management protocol that is suitable for Chinese patients with RPC. Therefore, this study reviewed therapeutic strategies such as adjuvant and neoadjuvant chemotherapy; molecular-targeted therapy; new treatments targeting tumor microenvironments, including immunotherapy and tumor vaccines; and therapies targeting special types of RPC during the past 20 years to provide a standard clinical management protocol for Chinese patients with RPC.